

Cancer  
 Children and Young Adult Cancer Services  
 Children's Cancer Network - Principal Treatment Centres

1746

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
PTC01	Proportion of patients aged 0-15 with a solid tumour with a recorded stage of 1 or 2 at diagnosis	Of those in the denominator, the number of patients with a solid tumour with a recorded stage of 1 or 2 at diagnosis within the period	The total number of patients with a solid tumour in the reporting period	3 year rolling	Annually	NCRAS	NCRAS		Metric in development. Not possible to report at present	N/A	N/A	N/A	Apr-20 - Mar-23
PTC02	Proportion of patients aged 0-15 with metastatic disease at diagnosis	Of those in the denominator, the number of patients with metastatic disease at diagnosis within the period	The total number of patients diagnosed in the reporting period	3 year rolling	Annually	NCRAS	NCRAS			N/A	N/A	N/A	Apr-20 - Mar-23
PTC03	Median time from onset of symptoms to diagnosis	Median time in days from date of onset of symptoms to date of diagnosis for patients diagnosed in the reporting period for patients aged 0-15 at time of diagnosis		3 year rolling	Annually	NCRAS			This metric is based on the COSD data item "cancer symptoms first noted date", which a record of the time when the symptoms were first noted related to a diagnosis as agreed between the consultant and the patient. Depending on the length of time this should normally include at least month and year data values. Day should also be included if known. If symptoms have been present for a long time then it may only be possible to record the year. The information is normally recorded by the clinical team that first sees the patient in secondary care.	N/A	N/A	N/A	Apr-20 - Mar-23
PTC04	Proportion of patients with leukaemia who progress or relapse.	Of those in the denominator, the number of patients who progress or relapse for patients with Leukaemia within the period	The total number of patients diagnosed with Leukaemia in the reporting period	1 year	Annually	Provider	Provider		The indicator measures the time, in days, from onset of symptoms to diagnosis for all cancer cases. We provide the median and range in time (including upper and lower quintiles) by PTC for patients diagnosed within the relevant age group and diagnosis year.	N/A	N/A	N/A	Apr-22 - Mar-23
PTC05	Proportion of patents with CNS tumours who progress or relapse.	Of those in the denominator, the number of patients who progress or relapse for patients with CNS tumour within the period for patients who are aged 0-15 at the start of the reporting period	The total number of patients diagnosed with CNS tumour in the reporting period	1 year	Annually	Provider	Provider		Numberator is where there is a recorded statement indicating that leukaemia has progressed or relapsed	N/A	N/A	N/A	Apr-22 - Mar-23
PTC06	Proportion of patients with non-CNS tumours who progress or relapse.	Of those in the denominator, the number of patients who progress or relapse for patients with non CNS solid tumours within the period who are aged 0-15 at the start of the reporting period	The total number of patients diagnosed with non CNS tumour in the reporting period	1 year	Annually	Provider	Provider		Numberator is where there is a recorded statement indicating that leukaemia has progressed or relapsed	N/A	N/A	N/A	Apr-22 - Mar-23
PTC07	Number of deaths within 30 days of chemotherapy	Count of deaths within 30 days of chemotherapy within the period		1 year	Annually	SUS			Number of patients with an episode of chemotherapy where the discharge destination is death within 30 days of a Chemotherapy episode and 22/23 NPOC code - NCBPSS1M Patients who's age is 0-15 at time of reporting	N/A	N/A	N/A	Apr-22 - Mar-23
PTC08	Proportion of eligible patients aged 0-15 recruited to a nationally available trial	Of those in the denominator, the number of eligible patients recruited to a nationally available trial within the period	The total number of patients eligible for a clinical trial in the reporting period	1 year	Annually	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23

Cancer  
 Children and Young Adult Cancer Services  
 Children's Cancer Network - Principal Treatment Centres

1746

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
PTC09	Proportion of patients aged 0-15 completing treatment, who receive an end of treatment summary within 6 months of the end of treatment.	Of those in the denominator, the number of patients completing treatment, who receive an end of treatment summary within 6 months of the end of treatment within the period	The total number of patients who have completed treatment in the reporting period	1 year	Annually	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
PTC10	Proportion of patients aged 0-15 offered the opportunity to tumour bank	Of those in the denominator, the number of patients offered the opportunity to tumour bank	The total number of patients diagnosed in the reporting period	1 year	Annually	NCRAS	NCRAS		From August 2020 the definition for this data item changed to include whether a patient was offered the opportunity to tumour bank. We will use these data when we report on diagnoses for 2020 onwards.	N/A	N/A	N/A	Apr-22 - Mar-23
PTC11	Proportion of patients aged 0-15 who have had tumour samples banked	The number of cases where tissues samples have been banked e.g those reported yes or where the patient was approached and consented	The total number of patients diagnosed in the reporting period	3 year rolling	Annually	NCRAS	NCRAS		This metric provides the proportion of cancer cases where there is a record of any tissue being banked at diagnosis, based on the COSD data definition collected up to August 2020 for the data item 'Banked tissue at diagnosis'. The denominator is based on all cases diagnosed with cancer. We considered whether this should only be for tumours with a tissue diagnosis but concluded that all tumours can have blood taken for germline mutations and all patients are theoretically offered blood tests for hereditary disposition.	N/A	N/A	N/A	Apr-20 - Mar-23
PTC12	Proportion of patients aged 0-15 admitted into ICU within 30 days of end of chemotherapy cycle	Of those in the denominator, the number of patients admitted into ICU within 30 days of end of chemotherapy cycle within the period	The total number of patients who have completed their chemotherapy cycle in the reporting period	3 year rolling	Annually	SUS	SUS		Patients to be identified with 22/23 NPOC code - NCBPSS51M	N/A	N/A	N/A	Apr-20 - Mar-23
PTC13	1 year survival	Of those in the denominator, the number who survive 1 year post date of diagnosis	The total number of patients diagnosed one year prior to the reporting period	3 year rolling	Annually	NCRAS	NCRAS		Metric in development. Not possible to report at present	N/A	N/A	N/A	Apr-20 - Mar-23
PTC14	5 year survival	Of those in the denominator, the number who survive 5 years post date of diagnosis	The total number of patients diagnosed five years prior to the reporting period	3 year rolling	Annually	NCRAS	NCRAS		Metric in development. Not possible to report at present	N/A	N/A	N/A	Apr-20 - Mar-23
PTC15	Proportion of patients aged 0-15 discussed at an age appropriate MDT	Number of cases discussed at a TYA, CTYA, paediatric MDT	Total number of cases diagnosed in the reporting period	3 year rolling	Annually	NCRAS	NCRAS		Please note the numerator is based on a record of discussion at MDT in the period of 3 months before diagnosis to 6 months after diagnosis.	N/A	N/A	N/A	Apr-20 - Mar-23
PTC16	Median time from onset of fever to administration of antibiotics in neutropenic fever in patients aged 0-15	Median time in days from date when fever is recorded for patients to the date of when administration of antibiotics in neutropenic fever is recorded during the reporting period.		1 year	Annually	Provider				N/A	N/A	N/A	Apr-22 - Mar-23